279 results on '"Hironaka S"'
Search Results
2. Effect of overlapping laser beams and density scale length in laser-plasma instability experiments on OMEGA EP
3. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma
4. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
5. 1259TiP Investigator-initiated phase II study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability—high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G/CA209-7W7)
6. 389P Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
7. Analysis of Sediment Dynamics in a River Basin Using a Process-based Approach
8. Evaluation of Sediment Transport Capacity Equations Using Basin Scale Process-Based Sediment Dynamic Modelling Approach
9. Evaluation of Sediment Transport Capacity Equations using Basin-scale Process-based Modelling Approach
10. 1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
11. P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study
12. 1488P A prognostic biomarker study in patients who underwent surgery or received chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
13. 104P Angiogenesis-related factors and clinical outcomes in combination therapy with paclitaxel (PTX), ramucirumab (RAM) plus nivolumab (Nivo) for advanced gastric cancer (AGC)
14. Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
15. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer
16. A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
17. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer
18. Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
19. Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
20. Evaluation of dual-bed pressure swing adsorption for CO 2 recovery from boiler exhaust gas
21. Influence of Oral Anaerobic Bacteria on Hematopoietic Stem Cell Transplantation Patients: Oral Mucositis and General Condition
22. A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer
23. 838TiP - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
24. The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer
25. A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
26. Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
27. CURRENT STATUS OF DENTAL INTERVENTION AND SAFETY MANAGEMENT IN THE DEMENTIA WARD
28. Examination of factors affecting the intraoral perception of object size: a preliminary study
29. Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study
30. LBA-003 - A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study)
31. SO-001 - Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer
32. 659P - Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
33. 627P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced esophageal cancer
34. 606TiP - Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G
35. 188P - A clinical validation study of RASKET-B: A multiple detection kit for RAS and BRAF gene mutations in colorectal cancer
36. 2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report
37. Evaluation of Sediment Transport Capacity Equations Using Basin Scale Process-Based Sediment Dynamic Modelling Approach
38. 765P - The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced small intestine cancer
39. 639P - A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies
40. 638P - Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab (ATTRACTION-01/ONO-4538-07)
41. Impacts of Progression Type on Overall Survival in Advanced Gastric Cancer: Randomized Piii Study of S-1 + Oxaliplatin Vs. S-1 + Cisplatin
42. Clinical Validation of a Novel Multiplex Kit for All Ras Mutations in Colorectal Cancer: Results of Rasket(Ras Key Testing) Prospective Multicenter Study
43. Randomized Phase Ii Study of S-1 Plus Oral Leucovorin (Sl) Versus Sl Plus Oxaliplatin (Sol) Versus S-1 Plus Cisplatin (Sp) in Patients with Advanced Gastric Cancer (Agc):Updated Overall Survival Data
44. Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status
45. 630P - Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study
46. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
47. Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II-III Esophageal Carcinoma
48. Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial
49. Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP)
50. Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.